Dihydroartemisinin Suppresses Hepatocellular Carcinoma Progression by Acting on KIF11 with PI3K/Akt Modulation
Cancers · 09.05.2026 · 18 (10) · 1530
DOI: 10.3390/cancers18101530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 09.05.2026. Verfasst von Aina Xiao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood Transfusion, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan 750002, China. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with limited effective therapies. Dihydroartemisinin (DHA), a derivative of artemisinin, exhibits potent antitumor activity, but its molecular mechanisms in HCC are unclear. Here, we identified kinesin family member 11 (KIF11) as a critical effector of DHA.
Methods
Bioinformatic analyses revealed that KIF11 is significantly upregulated in HCC and associated with poor prognosis, and gene expression profiling suggested its oncogenic role via the PI3K/Akt pathway. Functional studies demonstrated that DHA inhibits HCC cell proliferation, migration, invasion, and colony formation, while inducing apoptosis. Xenograft models of nude mice were established for validation.
Results
DHA downregulated KIF11 and epithelial–mesenchymal transition markers, whereas KIF11 overexpression attenuated DHA’s inhibitory effects; the inhibition of PI3K restored DHA sensitivity in KIF11-overexpressing cells. In vivo, DHA markedly suppressed tumor growth and malignancy in xenograft models, consistent with modulation of KIF11 and EMT-related proteins.
Conclusions
DHA exerts antitumor effects in HCC by acting via KIF11 and PI3K/Akt modulation, providing a potential therapeutic strategy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Blood Transfusion, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan 750002, China.
- Department of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Department of Laboratory Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China.
ORCID-Profile: Yu'E Liu, Wenjia Guo
Zitieren
APA
Xiao, A., Liu, Y., & Guo, W. (2026). Dihydroartemisinin Suppresses Hepatocellular Carcinoma Progression by Acting on KIF11 with PI3K/Akt Modulation. Cancers, 18(10), 1530. https://doi.org/10.3390/cancers18101530
Vancouver
Xiao A, Liu Y, Guo W. Dihydroartemisinin Suppresses Hepatocellular Carcinoma Progression by Acting on KIF11 with PI3K/Akt Modulation. Cancers. 2026;18(10):1530. doi:10.3390/cancers18101530
BibTeX
@article{Xiao2026,
author = {Xiao, Aina and Liu, Yu'E and Guo, Wenjia},
title = {Dihydroartemisinin Suppresses Hepatocellular Carcinoma Progression by Acting on KIF11 with PI3K/Akt Modulation},
journal = {Cancers},
year = {2026},
volume = {18},
number = {10},
pages = {1530},
doi = {10.3390/cancers18101530}
}
EUVIMED